Loading stock data…
ImmunityBio (IBRX)
$7.10-0.30 (-4.05%)
Market ClosedLast close Jul 24
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmunityBio, Inc. in the Healthcare sector is trading at $7.10 with a market capitalization of $7.2B. Wall Street consensus targets $13.00 (3 analysts), implying a +83.1% move over the next 12 months. The stock is currently 43% below its 52-week high of $12.43, remaining 22.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +83.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 26) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $44.21M↑ | $38.28M↑ | $32.06M↑ | $26.43M↑ | $16.52M |
| Gross Profit | $43.97M↑ | $37.90M↑ | $31.88M↑ | $26.29M↑ | $16.46M |
| Operating Income | -$69.79M↓ | -$64.68M↓ | -$55.63M↑ | -$71.28M↓ | -$64.43M |
| Net Income | -$632.78M↓ | -$61.94M↑ | -$67.25M↑ | -$92.56M↑ | -$129.65M |
Peer Comparison
JNJUNHPFE
Fundamentals
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases....
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$7.24B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
98.22%
Volume
Today's trading volume
8.50M
Recent News
ImmunityBio (IBRX) Could Be 41% Undervalued On Anktiva Optimism
ImmunityBio (IBRX) is back in focus after its stock surged 282.7% year to date, as investors weigh speculation around Anktiva’s role in bladder cancer treatment alongside ongoing regulatory and valuation questions. See our latest analysis for ImmunityBio. Recent trading shows that momentum in ImmunityBio’s share price has cooled in the near term, with a 7 day share price return down 12.16%, following a year to date share price return of 282.67% and a 1 year total shareholder return of...
Is ImmunityBio (IBRX) Reasonably Valued After Its 283% Rally?
ImmunityBio’s stock has surged 282.7% year to date, yet its overall valuation checks sit at a mixed 3 out of 6. This leaves investors weighing a powerful momentum story against signals that do not clearly flag the shares as cheap or expensive. The year to date gain of 282.7% suggests expectations around ImmunityBio have reset sharply higher. Fresh buyers are now paying a far richer price than they would have earlier in the year. Speculation around Anktiva’s potential role in bladder cancer...
SLS, IBRX Rise Overnight: Retail Bets On Big Pharma Buyouts As J&J Chases No. 1 Oncology Spot
J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.
IBRX Stock Climbs Premarket Despite Investor Stake Cut — Retail Sees ‘Imminent’ Global Rollout Catalyst
Sheets Smith Wealth Management cut its IBRX stake by 7.2% to 512,572 shares.
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout
Moderna, ImmunityBio, and Sarepta are all cratering today despite bullish recent news and no negative catalysts in sight, leaving investors scrambling to understand whether the biotech sector's monster 2026 run has finally hit a wall.